Skip to content Skip to footer
Subscribe Now

INSIGHTS+

PharmaShots' Key Highlights of Second Quarter 2019
PharmaShots’ Key Highlights of Second Quarter 2019
The second quarter of 2019 has ended with major acquisitions in pharma and biotech industry. Moving with the latest acquisition of Allergan for $63B by AbbVie focusing on to generate revenue with addition of Allergan's medical aesthetics and ophthalmology portfolio. Prior to that, Pfizer acquired Array Biopharma for $11.4B to expand its oncology portfolio. Some…
July 3, 2019
Insights+ Key Biosimilars Events of May 2019
Insights+ Key Biosimilars Events of May 2019
Biosimilars are going in market with vast emerging needs of people for multiple diseases. The biologics that are too costly to be used in the markets. Hence physicians are developing biosimilars a reference product to biologics which are biologically similar to biologics. Our team at PharmaShots have summarized some of the news regarding biosimilars in…
June 4, 2019
Insights+: Breakthrough Therapy Designation by the US FDA in 2018
Insights+: Breakthrough Therapy Designation by the US FDA in 2018
Breakthrough Therapy (BT) Designation is an expedited review program introduced in Section 902 of the Food and Drug Safety and Innovation Act of 2012. The Breakthrough Designation is granted to the drugs as monotherapy or in combination with other drugs intended to treat serious or life-threatening diseases and has shown substantial improvement over available therapies…
May 8, 2019
Insights+: The US FDA New Drug Approvals in 2018
Insights+: The US FDA New Drug Approvals in 2018
1. Janssen's Erleada (apalutamide) Receives FDA Approval for Non-Metastatic Castration-Resistant Prostate Cancer (NM-CRPC) Published: 14 Feb,2018 | Tags: Janssen, Erleada, apalutamide, Receives, FDA, Approval, Non-Metastatic Castration-Resistant Prostate Cancer, NM-CRPC 2. Helsinn's (fosnetupitant + palonosetron) Receives FDA Approval for Managing Chemotherapy-Induced Nausea and Vomiting (CINV) Published: 14 Feb,2018 | Tags: Helsins, fosnetupitant + palonosetron, Receives, FDA, Approval, Managing Chemotherapy-Induced Nausea and Vomiting,…
March 4, 2019
PharmaShots Year in Review: Biosimilars Approvals in 2018
PharmaShots Year in Review: Biosimilars Approvals in 2018
THE US FDA APPROVALS  1.  Pfizer's Retacrit (epoetin alfa-epbx, biosimilar) Receives FDA Approval for Anemia Published: 15 May, 2018  | Tags: Pfizer, Retacrit, epoetinalfa-epbx, biosimilar, Receives, FDA, Approval, Anemia 2.   Pfizer's Nivestym (filgrastim-aafi, biosmilar) Receives FDA Approval for Neutropenia   Published: 20 Jul, 2018 | Tags: (filgrastim-aafi approval biosmilar), Neutropenia, Nivestym, Pfizer, Receives, the US FDA 3.  Sandoz's Hymiroz (adalimumab-adaz, biosimilar) Receives the US FDA…
January 8, 2019
PharmaShots' Most Read News of 2018
PharmaShots’ Most Read News of 2018
PharmaShots' Most Read News of 2018 | Top 10 Pharma News of 2018  1. Celgene to Acquire Juno for its Cellular Immunotherapy & Hematology Portfolio Published: 22 Jan, 2018 | Tags: Celgene,  Acquire, Juno, Cellular, Immunotherapy, Hematology Portfolio 2.  Sanofi to Acquire Bioverativ for its Hemophilia Products Published: 22 Jan, 2018 | Tags: Sanofi, Acquire, Bioverativ, Treat,…
January 2, 2019